ADC THERAPEUTICS Trademark

Trademark Overview

On Monday, January 11, 2016, a trademark application was filed for ADC THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the ADC THERAPEUTICS trademark a serial number of 86983735. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Tuesday, February 4, 2025. This trademark is owned by ADC Therapeutics SA. The ADC THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:

Providing medical information; providing information in the fields of healthcare, therapeutic properties of pharmaceuticals, and health

Pharmaceutical drug development services; providing medical and scientific research information in the field of pharmaceuticals
adc therapeutics

General Information

Serial Number86983735
Word MarkADC THERAPEUTICS
Filing DateMonday, January 11, 2016
Status710 - CANCELLED - SECTION 8
Status DateTuesday, February 4, 2025
Registration Number5516437
Registration DateTuesday, July 17, 2018
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, May 1, 2018

Trademark Statements

Description of MarkThe mark consists of the letters "A", "D", and "C" and the word "THERAPEUTICS".
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesProviding medical information; providing information in the fields of healthcare, therapeutic properties of pharmaceuticals, and health
NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesPharmaceutical drug development services; providing medical and scientific research information in the field of pharmaceuticals

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateTuesday, February 4, 2025
Primary Code042
First Use Anywhere DateWednesday, November 30, 2011
First Use In Commerce DateWednesday, November 30, 2011
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateTuesday, February 4, 2025
Primary Code044
First Use Anywhere DateWednesday, November 30, 2011
First Use In Commerce DateWednesday, November 30, 2011

Trademark Owner History

Party NameADC Therapeutics SA
Party Type30 - Original Registrant
Legal Entity Type33 - NOT AVAILABLE
AddressEPALINGES 1066
CH
Party NameADC Therapeutics SA
Party Type20 - Owner at Publication
Legal Entity Type33 - NOT AVAILABLE
AddressEpalinges 1066
CH
Party NameADC Therapeutics SA
Party Type10 - Original Applicant
Legal Entity Type33 - NOT AVAILABLE
AddressEpalinges 1066
CH

Trademark Events

Event DateEvent Description
Tuesday, May 3, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, January 14, 2016NEW APPLICATION ENTERED
Tuesday, January 19, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 26, 2016ASSIGNED TO EXAMINER
Tuesday, May 3, 2016NON-FINAL ACTION E-MAILED
Tuesday, May 3, 2016NON-FINAL ACTION WRITTEN
Thursday, November 3, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, November 3, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 3, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 13, 2016FINAL REFUSAL WRITTEN
Tuesday, December 13, 2016NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, December 13, 2016FINAL REFUSAL E-MAILED
Tuesday, June 13, 2017TEAS AMENDMENT OF USE RECEIVED
Tuesday, June 13, 2017TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, June 13, 2017USE AMENDMENT FILED
Tuesday, June 13, 2017EXPARTE APPEAL RECEIVED AT TTAB
Tuesday, June 13, 2017EX PARTE APPEAL-INSTITUTED
Tuesday, June 13, 2017JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, July 19, 2017ASSIGNED TO LIE
Monday, July 24, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 24, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 27, 2017AMENDMENT TO USE PROCESSING COMPLETE
Monday, August 28, 2017USE AMENDMENT ACCEPTED
Monday, August 28, 2017NON-FINAL ACTION WRITTEN
Monday, August 28, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 28, 2017NON-FINAL ACTION E-MAILED
Tuesday, August 29, 2017NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Tuesday, February 27, 2018DIVISIONAL REQUEST RECEIVED
Tuesday, February 27, 2018TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, February 27, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 5, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, March 6, 2018DIVISIONAL PROCESSING COMPLETE
Wednesday, March 21, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, March 21, 2018TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, March 21, 2018PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Thursday, March 29, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 11, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 1, 2018PUBLISHED FOR OPPOSITION
Thursday, October 20, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 1, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 17, 2018REGISTERED-PRINCIPAL REGISTER
Thursday, October 20, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, October 20, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 20, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, July 17, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, February 4, 2025CANCELLED SEC. 8 (6-YR)
Wednesday, February 1, 2023ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Thursday, October 20, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, October 26, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

Related Keywords

therapeutics providing information pharmaceuticals medical services development scientific field research drug